Innovation Center ● Prof. Dr. med. Martin Bornhäuser
Hematology and Cell Therapy
DIRECTOR
Prof. Dr. med. Martin Bornhäuser
University Hospital Carl Gustav Carus Dresden
Medical Clinic I
Department of Hematology, Cell Therapy and Medical Oncology
Fetscherstraße 74
01307 Dresden
Short vita
Prof. Martin Bornhäuser is Director of the Medical Clinic and Polyclinic I of the Carl Gustav Carus University Hospital of the TU Dresden. Furthermore, he is one of the managing directors at the National Center for Tumor Diseases Dresden (NCT/UCC).
Prof. Bornhäuser completed his training at the University of Kiel, where he received his doctorate at the Institute of Sports Medicine. From 1993 to 1994, he worked in hematology and medical oncology at the University Hospital of Tübingen. Prof. Bornhäuser is a specialist in internal medicine, hematology and oncology. He is an internationally recognized expert in the treatment of leukemias and in stem cell transplantation and cellular immunotherapy.
Research and development
- New forms of allogeneic stem cell transplantation
- Use of cell therapeutics
- Therapy optimization studies in leukemias and in the field of stem cell transplantation
- Use of artificial intelligence in the diagnosis and prognosis prediction of leukemias
Expertise
- Diagnostics and therapy of malignant diseases of the hematopoietic system
- Precision Oncology
- Cell and immunotherapy
References
1. Röllig C, et al. Bornhäuser M. Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia? Blood. 2020 Aug 13;136(7):823-830.
2. Schetelig J et al. Bornhäuser M. External validation of models for KIR2DS1/KIR3DL1-informed selection of hematopoietic cell donors fails. Blood. 2020 Apr 16;135(16):1386-1395. doi: 10.1182/blood.2019002887. PMID: 31932846.
3. Fassslrinner F et al. Bornhäuser M. Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial. Lancet Haematol 2018 Apr;5(4):e161-e169
4. Röllig C, Knop S, Bornhäuser M. Multiple Myeloma. Lancet. 2015 30;385(9983):2197-208
5. Prewitz MC, et al., Bornhäuser M, Werner C. (2013) Tightly anchored tissue-mimetic matrices as instructive stem cell microenvironments. Nat Methods;10:788-94.
6. Bornhäuser M, Kienast J, Trenschel R, et al. (2012) Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol; 3:1035-44.
7. Bornhäuser M, Thiede C, Platzbecker et al. (2011) Prophylactic transfer of BCR-ABL-, PR1-, and WT1-reactive donor T cells after T cell-depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia. Blood. 117:7174-84.
Event
On behalf of Prof. Dr. med. Bornhäuser, the GWT organizes annually numerous events around current issues and topics in the fields of hematology, medical oncology and cell therapy.
DSHO EVENT PAGE
Thank you for your interest in our services. We gladly answer your enquiries!
